Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of divalent manganese in the preparation of immune enhancing drugs or antitumor drugs

A technology of divalent manganese and antitumor agent, which is applied in the field of medicine to achieve the effects of reducing economic burden, promoting proliferation and enhancing therapeutic effect

Active Publication Date: 2022-03-29
PEKING UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, there have been no reports of divalent manganese activating antitumor responses by activating systemic responses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of divalent manganese in the preparation of immune enhancing drugs or antitumor drugs
  • Application of divalent manganese in the preparation of immune enhancing drugs or antitumor drugs
  • Application of divalent manganese in the preparation of immune enhancing drugs or antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0059] The preparation method of the present invention will be further described in detail in conjunction with specific examples below. It should be understood that the following examples are only for illustrating and explaining the present invention, and should not be construed as limiting the protection scope of the present invention. All technologies realized based on the above contents of the present invention are covered within the scope of protection intended by the present invention.

[0060] The reagents and materials used in the following examples can be obtained from commercial sources unless otherwise specified.

[0061] Materials and methods

[0062] Antibodies and Reagents

[0063] Antibody sources are as follows: anti-GAPDH antibody (sc-25778) was purchased from Santa Cruz. cGAS antibody (31659S) and STING antibody (13647S) were purchased from Cell Signaling Technology. Antibodies against Viperin were made and used by published methods (13). Briefly, the...

Embodiment 1

[0095] Example 1. Construction of mouse tumor model

[0096] Experiment (A) method for mouse tumor model construction

[0097] Such as figure 1 A shows a brief flowchart of the tumor inoculation method used in the experiment.

[0098] Experiment (B) Construction of mouse subcutaneous tumor model

[0099] Inject 10 subcutaneously in the groin of 6-8 week-old wild-type C57BL / 6 mice 5 It generally takes 2 weeks for tumor cells of several orders of magnitude to grow and construct a subcutaneous tumor model.

[0100] Experiment (C) Construction of mouse lung metastasis tumor model

[0101] Inoculate 6-8 week-old wild-type C57BL / 6 mice with 2 × 10 5 A B16F10 melanoma cell is transferred, and the lung metastasis model is constructed, which usually takes 2 weeks.

Embodiment 2

[0102] Embodiment 2. mouse nasal cavity instillation Mn 2+ Effective in both subcutaneous melanoma and pulmonary metastatic melanoma

[0103] Experiment (A) Mn 2+ Changes in Growth of Subcutaneous Melanoma in Mice After Treatment

[0104] Subcutaneously inject 5×10 5 A PBS suspension of B16F10 cells was divided into two groups. The experimental group started nasal instillation of MnCl at a dose of 5 mg / kg 24 hours after tumor inoculation. 2 normal saline solution, and the same volume of normal saline solution was instilled into the nasal cavity of the control group, once every 2 days. After the tumor grew to be palpable, the size of the tumor was measured, recorded every 2 days, and the tumor growth curve was drawn. Control group n=10, experimental group n=10.

[0105] Experiment (B) Comparison of Mn by in vivo imaging 2+ Differences in tumors at different time points during treatment

[0106] Take the mouse to be tested, inject 150mg / kg of the firefly luciferase su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of divalent manganese in the preparation of immune-enhancing drugs or anti-tumor drugs, in particular to divalent manganese as an activator of dendritic cells, macrophages or CD8 positive T cells and its use in dendritic cells, macrophages or CD8 positive T cells. Use of macrophage or CD8 positive T cell activators. The present invention also provides a sensitizer used by the activator to enhance the effect of tumor drugs. When administered in combination with anti-tumor drugs, the dose of anti-tumor drugs can be significantly reduced to achieve a good therapeutic effect.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of divalent manganese in the preparation of immune enhancing drugs or antitumor drugs. Background technique [0002] Tumor treatment methods currently mainly include surgery, radiation therapy, chemotherapy, adoptive cell transfer therapy, and immune checkpoint inhibitor therapy. Currently, adoptive cell transfer therapy represented by Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T), and Programmed cell Death protein-1 (PD-1) Antibody (anti-PD-1) and cytotoxic T cell-associated antigen 4 (Cytotoxic T lymphocyte antigen-4, CTLA-4) antibody (anti-CTLA-4) are immunotherapy represented by immune checkpoint inhibitor therapy. mainstay of cancer treatment. Although the above-mentioned treatment methods are more effective in some specific types of tumors such as Hodgkin's lymphoma, desmoplastic melanoma and Merkel cell carcinoma, for patients with other types...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K33/32A61K39/39A61K45/06A61P35/00A61P37/04A61P31/00
CPCA61K33/32A61K39/39A61K45/06A61P35/00A61P37/04A61P31/00A61K2039/55505A61K2300/00
Inventor 蒋争凡吕梦泽王晨光张睿
Owner PEKING UNIV